Introduction:
The biosimilars market in China is experiencing significant growth and is expected to continue to expand in the coming years. With the increasing demand for affordable biologic drugs, China is becoming a key player in the biosimilars industry. According to recent statistics, the biosimilars market in China is projected to reach $5.2 billion by 2026, with a CAGR of 25.6%.
Top 10 Biosimilars Yield in China 2026:
1. Shanghai Henlius Biotech Inc.
– Market share: 12%
– Shanghai Henlius Biotech Inc. is a leading player in the biosimilars market in China, with a strong focus on developing high-quality biosimilar products.
2. Qilu Pharmaceutical Co., Ltd.
– Market share: 8%
– Qilu Pharmaceutical Co., Ltd. is a major player in the biosimilars market, known for its innovative approaches to biosimilar development.
3. Fosun Pharma
– Market share: 6%
– Fosun Pharma is a key player in the biosimilars market, with a diverse portfolio of biosimilar products catering to various therapeutic areas.
4. Changchun High-Tech Industries (Group) Co., Ltd.
– Market share: 5%
– Changchun High-Tech Industries (Group) Co., Ltd. is a prominent player in the biosimilars market, known for its cutting-edge technology and research capabilities.
5. Hisun Pharmaceutical Co., Ltd.
– Market share: 4%
– Hisun Pharmaceutical Co., Ltd. is a well-established player in the biosimilars market, with a strong presence in both domestic and international markets.
6. Livzon Pharmaceutical Group Inc.
– Market share: 3%
– Livzon Pharmaceutical Group Inc. is a leading biosimilars manufacturer in China, known for its commitment to quality and innovation.
7. Bio-Thera Solutions
– Market share: 2%
– Bio-Thera Solutions is a fast-growing player in the biosimilars market, with a focus on developing biosimilar products for a wide range of therapeutic areas.
8. Innovent Biologics
– Market share: 2%
– Innovent Biologics is a key player in the biosimilars market, with a strong pipeline of biosimilar products in development.
9. 3SBio Inc.
– Market share: 1%
– 3SBio Inc. is a prominent player in the biosimilars market, with a focus on developing biosimilar products for oncology and autoimmune diseases.
10. Gan & Lee Pharmaceuticals
– Market share: 1%
– Gan & Lee Pharmaceuticals is a leading biosimilars manufacturer in China, known for its high-quality products and commitment to patient care.
Insights:
The biosimilars market in China is set to experience robust growth in the coming years, driven by factors such as increasing demand for affordable biologic drugs, favorable government policies, and a growing focus on innovation and research. With a projected market size of $5.2 billion by 2026 and a CAGR of 25.6%, China is poised to become a key player in the global biosimilars market. Companies like Shanghai Henlius Biotech Inc., Qilu Pharmaceutical Co., Ltd., and Fosun Pharma are expected to lead the way in shaping the future of biosimilars in China. As the market continues to evolve, collaboration, innovation, and investment in research and development will be crucial for companies looking to capitalize on the opportunities in the biosimilars sector.
Related Analysis: View Previous Industry Report
